Hi-Clearance

TWO:1788 Taiwan Medical Devices
Market Cap
$184.35 Million
NT$6.10 Billion TWD
Market Cap Rank
#18056 Global
#796 in Taiwan
Share Price
NT$137.00
Change (1 day)
-0.36%
52-Week Range
NT$135.50 - NT$144.50
All Time High
NT$149.30
About

Hi-Clearance Inc. supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan. The company offers dialyzers, dialysis and RO machines, and related consumables and drugs; interventional cardiology and radiology, and vascular surgery devices; dental consumables, implant materials, and equipment; and blood glucose monitors, and related consumabl… Read more

Hi-Clearance (1788) - Net Assets

Latest net assets as of September 2025: NT$2.96 Billion TWD

Based on the latest financial reports, Hi-Clearance (1788) has net assets worth NT$2.96 Billion TWD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.99 Billion) and total liabilities (NT$2.03 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$2.96 Billion
% of Total Assets 59.34%
Annual Growth Rate 7.81%
5-Year Change 49.12%
10-Year Change N/A
Growth Volatility 6.89

Hi-Clearance - Net Assets Trend (2015–2024)

This chart illustrates how Hi-Clearance's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hi-Clearance (2015–2024)

The table below shows the annual net assets of Hi-Clearance from 2015 to 2024.

Year Net Assets Change
2024-12-31 NT$3.00 Billion +0.61%
2023-12-31 NT$2.98 Billion +22.31%
2022-12-31 NT$2.44 Billion +5.89%
2021-12-31 NT$2.30 Billion +14.44%
2020-12-31 NT$2.01 Billion +12.82%
2019-12-31 NT$1.78 Billion +8.74%
2018-12-31 NT$1.64 Billion +0.98%
2017-12-31 NT$1.63 Billion +4.30%
2016-12-31 NT$1.56 Billion +2.10%
2015-12-31 NT$1.53 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Hi-Clearance's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 92.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings NT$992.32 Million 33.06%
Other Components NT$2.01 Billion 66.94%
Total Equity NT$3.00 Billion 100.00%

Hi-Clearance Competitors by Market Cap

The table below lists competitors of Hi-Clearance ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hi-Clearance's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,983,868,000 to 3,001,923,000, a change of 18,055,000 (0.6%).
  • Net income of 359,688,000 contributed positively to equity growth.
  • Dividend payments of 311,647,000 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income NT$359.69 Million +11.98%
Dividends Paid NT$311.65 Million -10.38%
Other Changes NT$-29.99 Million -1.0%
Total Change NT$- 0.61%

Book Value vs Market Value Analysis

This analysis compares Hi-Clearance's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.03x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.96x to 2.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 NT$46.23 NT$137.00 x
2018-12-31 NT$46.68 NT$137.00 x
2019-12-31 NT$45.80 NT$137.00 x
2020-12-31 NT$49.22 NT$137.00 x
2021-12-31 NT$56.19 NT$137.00 x
2022-12-31 NT$59.49 NT$137.00 x
2023-12-31 NT$67.02 NT$137.00 x
2024-12-31 NT$67.43 NT$137.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hi-Clearance utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.98%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.83%
  • • Asset Turnover: 0.82x
  • • Equity Multiplier: 1.65x
  • Recent ROE (11.98%) is below the historical average (14.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 14.21% 7.92% 1.13x 1.59x NT$64.29 Million
2016 13.35% 7.33% 1.15x 1.59x NT$52.03 Million
2017 15.45% 8.49% 1.13x 1.61x NT$88.57 Million
2018 14.84% 7.87% 1.04x 1.81x NT$79.35 Million
2019 13.77% 7.58% 0.87x 2.09x NT$67.29 Million
2020 15.76% 9.25% 0.82x 2.09x NT$115.98 Million
2021 15.13% 9.46% 0.83x 1.93x NT$118.21 Million
2022 15.02% 7.81% 1.04x 1.85x NT$122.48 Million
2023 11.66% 8.93% 0.84x 1.55x NT$49.60 Million
2024 11.98% 8.83% 0.82x 1.65x NT$59.50 Million

Industry Comparison

This section compares Hi-Clearance's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $1,082,246,778
  • Average return on equity (ROE) among peers: 5.96%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hi-Clearance (1788) NT$2.96 Billion 14.21% 0.69x $104.25 Million
Health & Life Co., Ltd. (1781) $372.58 Million -4.71% 1.15x $12.97 Million
Radiant Innovation (3373) $865.89 Million -3.30% 0.08x $18.65 Million
Wellell Inc (4106) $1.31 Billion 13.81% 0.24x $37.12 Million
Rossmax International Ltd (4121) $1.33 Billion 1.93% 1.30x $38.32 Million
United Orthopedic (4129) $1.77 Billion 7.55% 0.46x $300.33 Million
Dynamic Medical Technologies (4138) $1.76 Billion 11.67% 0.71x $39.41 Million
Ok Biotech Co Ltd (4155) $1.30 Billion 9.66% 0.71x $44.61 Million
Bioptik Technology (4161) $717.83 Million 6.76% 1.11x $30.42 Million
EPS Bio Technology Corp. (4183) $309.15 Million 10.25% 0.77x $4.27 Million